CA-LIGHTBITS-LABS
23.6.2020 15:02:08 CEST | Business Wire | Press release
Lightbits Labs , the originator and leader in NVMe™ over TCP (NVMe/TCP) software-defined block storage, today launched LightOS® 2.0, enabling full cloud-native persistent storage integration for Kubernetes with unprecedented scaling and availability via clustering.
With the efficiency and convenience of all-flash arrays and the high performance of direct-attached flash storage, LightOS 2.0 enables independent scaling of compute and storage. This solution maximizes Kubernetes functionality, provides ease of migration and delivers fast recovery times following server failure. LightOS 2.0 provides virtual NVMe volumes, delivering low latency and high performance, while at the same time providing high availability via seamless target-side storage server failover. The result is no interruption in service or forced migration due to a drive or storage node failure.
“Lightbits Labs is the only storage solution in production in the market today that allows data centers to take full advantage of NVMe/TCP,” said Lip-Bu Tan, Lightbits Board Member and Founding Managing Partner of WRVI Capital. “The advancements in LightOS 2.0 will ensure that customers can easily scale their infrastructure, and in-turn their business, without compromising performance, efficiency, or cost.”
LightOS 2.0 leverages a Container Storage Interface (CSI) plugin for Kubernetes to address the growing need for third-party storage support for stateful container storage needs. This has become more important as Kubernetes microservices move from stateless to stateful applications. LightOS 2.0 is ideal for containerized environments like Kubernetes that require large-scale clusters with persistent and durable storage for rapid node migration, workload rebalancing, or recovery from failure without copying data over the network. If any computer node in the network fails, data is moved virtually by pointing it to another container. Taken together, LightOS 2.0 allows for lower TCO via higher capacity utilization as well as increased operational efficiency via decreased downtime and infrastructure flexibility.
“At cloud scale, everything fails. LightOS 2.0 is the industry’s first NVMe/TCP scale-out clustered storage solution – protecting against data loss and avoiding service interruptions at scale in the presence of SSD, server, storage, or network failures,” said Kam Eshghi, Chief Strategy Officer at Lightbits Labs . “Now containerized applications can enjoy all of the benefits of disaggregated storage using LightOS CSI plugin for Kubernetes, spinning up persistent storage volumes for containerized workloads just as easily as spinning up another container.”
When installed on commodity servers in large-scale data centers, LightOS 2.0 is automatically optimized for I/O intensive compute clusters, such as Kafka, Cassandra, MySQL, MongoDB, and time series databases. Each storage server in the cluster can support up to 64K namespaces and 16K connections. With LightOS 2.0 providing a highly available and durable storage layer, application teams can focus their efforts on developing new services while LightOS 2.0 takes care of the underlying whole storage platform, guaranteeing the availability of and high-performance access to the data.
“It’s clear that customers want on-demand, high performance, always-available storage no matter where their workloads run. As applications move to the edge, we’re excited about the potential of Lightbits LightOS 2.0 to leverage our rich, interconnected datacenter fabrics, providing local flash-style performance without the operational and reliability issues of server installed drives.” – Zachary Smith, Managing Director for Bare Metal, Equinix
LightOS 2.0 provides the following benefits:
- Software-defined disaggregated storage for cloud data centers delivering direct-attached NVMe SSD performance and up to a 50% reduction in tail latency
- Optimized for low-cost QLC flash: Extends write endurance of drives and improves write performance without the need to modify applications
- Fast container migration via CSI persistent and durable storage
- Standards-based NVMe/TCP block storage access protocol for application-server-to-storage-server communication
- LightOS clusters leverage standard NVMe-oF 1.1 multipathing with data protection on the storage target side, providing transparency to the client with fast failover
- Distributed and durable cluster management with fast failover handling
- No single point of failure in data and control paths
- Multiple LightOS clusters can exist in the same cloud data center and clients can use multiple clusters simultaneously
- Support for Kubernetes v1.13 and v1.15 - v1.18 and later for any volume size, number of volumes or Kubernetes size cluster
- Rolling upgrades allow for LightOS updates without disruption to storage clients
- Target-side solution that is easy to deploy at scale, without having to touch the network infrastructure or the clients
- In cases where Kubernetes is integrated with the OpenStack platform, LightOS 2.0 allows for stateful containers through Kubernetes via CSI, or via a Cinder plugin
“LightOS 2.0 is game changing for the data center. It transforms a rack of x86 servers with NVMe drives into a large high-performance highly redundant storage pool connected to applications servers via NVMe/TCP with Kubernetes integration and high availability. Everything is standard in the solution – TCP protocol on Ethernet, network switches, NICs and drivers – without the need to consider specialized and costly new network infrastructure. Thus LightOS protects current investments and boosts deployments at no risk to deliver new SLA levels for modern application workloads. This is the perfect illustration of the Software-Defined Storage philosophy,” says Philippe Nicolas, Analyst Coldago Research.
To learn more about LightOS 2.0, join our upcoming webinar on June 30th at 10 a.m. PT, “Kubernetes Assimilation: Persistence is Futile .” Josh Goldenhar, VP of Product Marketing, will discuss how you can deploy high performance, low latency block storage in Kubernetes environments and get great performance, increased reliability and lower cost. Register now to save your seat.
Lightbits Labs Resources
- LightOS 2.0 Product Overview: Software-Defined Composable Storage
- Kubernetes and LightOS: Performance, Persistence, Simplicity
- Apache Kafka and LightOS
- Lightbits Labs Gears Up for Significant Market Adoption of NVMe/TCP in 2020 (press release)
- Lightbits Labs Named Storage Company of the Year (press release)
About Lightbits Labs™
Lightbits Labs, founded in 2016, is a software-defined storage company that brings hyperscale efficiency and flexibility to everyone. Lightbits’ solution delivers composable, disaggregated NVMe/TCP software-defined storage that performs like local Flash. The company pioneered NVMe/TCP so the solution is easy to deploy at scale, while delivering performance that from applications’ perspective is indistinguishable from local SSDs. Lightbits Labs is backed by strategic investors including Dell Technologies Capital, Cisco Investments and Micron, as well as top investors and VCs including Avigdor Willenz, Lip-Bu Tan, Marius Nacht, SquarePeg Capital, and WRVI Capital.
Learn more at www.lightbitslabs.com or contact us at info@lightbitslabs.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200623005228/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
